ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Sees Significant Increase in Short Interest

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) was the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 20,100 shares, a growth of 272.2% from the August 31st total of 5,400 shares. Based on an average daily volume of 13,500 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily volume of 13,500 shares, the days-to-cover ratio is currently 1.5 days.

ALPS Medical Breakthroughs ETF Trading Up 2.1%

Shares of SBIO stock opened at $39.85 on Friday. ALPS Medical Breakthroughs ETF has a fifty-two week low of $22.33 and a fifty-two week high of $42.73. The stock has a 50 day moving average price of $35.46 and a two-hundred day moving average price of $31.46.

Institutional Trading of ALPS Medical Breakthroughs ETF

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in ALPS Medical Breakthroughs ETF in the second quarter valued at approximately $82,000. Ally Invest Advisors Inc. purchased a new position in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at approximately $200,000. Strategic Financial Services Inc. increased its stake in shares of ALPS Medical Breakthroughs ETF by 97.8% during the second quarter. Strategic Financial Services Inc. now owns 38,032 shares of the company’s stock valued at $1,144,000 after buying an additional 18,807 shares during the period. Moran Wealth Management LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at approximately $300,000. Finally, Jones Financial Companies Lllp purchased a new position in shares of ALPS Medical Breakthroughs ETF during the first quarter valued at approximately $782,000.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.